IMA vs LIN · rev $9.2M vs P/E 34, rev $33.99B
ImageneBio, Inc. (IMA) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
IMA currently screens at market cap $64.7M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the IMA and LIN stock pages for the full models.
Not investment advice.